跳至主要内容
临床试验/NCT06119386
NCT06119386已完成不适用

Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease

Centro Oculistico Borroni2 个研究点 分布在 1 个国家目标入组 81 人开始时间: 2022年11月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
81
试验地点
2
主要终点
Ocular surface evaluation

研究概览

简要总结

To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

详细描述

To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

In this prospective, interventional study, 81 patients will be randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group).

Outcomes measures will include ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade at baseline, 1-month and 3-months follow-up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • > 18 years old with a self-reported history of DED
  • OSDI score ≥ 33 points
  • TBUT less than 10 seconds.

排除标准

  • skin pathologies that prevent QRM treatment
  • corneal infection and corneal dystrophies
  • active ocular allergies
  • intraocular surgery or laser ocular surgery

结局指标

主要结局

Ocular surface evaluation

时间窗: 3 month

Tear meniscus height (TMH) measured in millimeters

次要结局

未报告次要终点

研究者

发起方
Centro Oculistico Borroni
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验